This ASX stock is going parabolic, and I think it's still a buy

4DMedical shares are up nearly 500% in 2025, but improving revenue visibility suggests the growth story may not be over.

Key points
  • 4DMedical's share price has surged nearly 500% in 2025, thanks to expanding market reach and validation through commercial agreements.
  • The company's advanced lung imaging technology offers significant improvements in diagnosing and monitoring respiratory conditions, gaining traction with hospitals.
  • Despite recent gains, the company remains a strong growth candidate with further market expansion and increased technology adoption potential, while recognising inherent volatility and execution risks.

Shares in 4DMedical Ltd (ASX: 4DX) have been nothing short of extraordinary in 2025. What started the year as a relatively unknown small-cap healthcare name has turned into one of the ASX's standout momentum stories.

At Wednesday's close, shares in the respiratory imaging technology company finished at $2.83, down 5% amid broader market volatility.

Even after that pullback, the stock is still up close to 500% in 2025.

It's easy to assume most of the upside is already gone. But a closer look suggests there may still be more left in this growth stock.

Medical workers examine an x-ray or scan in a hospital laboratory.

Image source: Getty Images

What does 4DMedical actually do?

4DMedical operates in medical imaging, using software to turn standard CT scans into highly detailed, four-dimensional images of lung function. Its core XV Technology gives clinicians a clearer picture of how a patient's lungs are actually working, revealing issues traditional imaging can miss, especially in chronic and complex respiratory conditions.

That matters because many lung diseases are hard to diagnose and monitor using existing tools. Hospitals and clinicians are always looking for better ways to assess, track, and treat conditions like COPD, asthma, and post-COVID complications. 4DMedical's software is designed specifically to help solve that problem.

Why has the share price exploded?

The recent rally has not been driven by hype alone. Over the past few months, 4DMedical has delivered a steady stream of positive news.

Key regulatory approvals in major overseas markets, including Canada, have significantly expanded its addressable customer base. At the same time, the company has announced new commercial agreements and partnerships that validate its technology in real-world clinical settings.

Importantly, these updates have shifted investor perception. 4DMedical is no longer seen purely as an early-stage biotech with promise, but as a business starting to turn its technology into revenue.

Revenue is becoming more visible

Until recently, 4DMedical shares were largely priced on future potential. However, that's starting to change as revenue becomes more visible.

Software sales are growing, more hospitals are using the product, and interest from overseas customers is increasing. The company isn't profitable yet, but as a software business, more users should improve the numbers over time.

This has prompted the market to reassess the stock.

What could go wrong and what could go right?

None of this comes without risk. The share price has already moved sharply, volatility is likely to remain high, and expectations are rising. Slower execution or weaker adoption would likely impact the stock.

Even so, the longer-term opportunity is still there. If 4DMedical continues to expand into new markets and sees its technology adopted more widely in clinical settings, today's valuation could still have room to grow.

The bottom line

4DMedical has been one of the ASX's stronger performers in 2025.

For investors who understand the risks and are comfortable with volatility, this parabolic ASX stock still looks like one worth keeping firmly on the watchlist, even after its huge run.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Male and female scientists analysing data on a computer.
Healthcare Shares

Why I'd buy this ASX biotechnology company over CSL

The potential for research-driven growth could be large.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Neuren Pharmaceuticals shares just hit a 12-month high. There could be more good news to come

This week's sales figures were impressive.

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

Do I still rate CSL shares as a buy after rising 120% in four months?

Let's see if it is too late to buy this biotech giant's shares.

Read more »

a man wearing old fashioned aviator cap and goggles emerges from the top of a cannon pointed towards the sky. He is holding a phone and taking a selfie.
Healthcare Shares

CSL shares push past $200: Is $250 next?

How much further can the CSL share price rally go?

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

ResMed or Cochlear: Which ASX healthcare share would I buy today?

I like both businesses for the long term, but their recent financial performances have given me something to think about.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Could Telix Pharmaceuticals shares double in value over the next 12 months?

Find out if the ASX biotech stock is a buy, sell, or hold now.

Read more »

A doctor appears shocked as he looks through binoculars on a blue background.
Healthcare Shares

3 compelling reasons to consider buying Mesoblast shares

This company has a lot going on, plus strong revenues.

Read more »

Doctor with stethoscope typing on her computer.
Healthcare Shares

Are CSL shares a buy, hold, or sell at their 52-week high?

Investors have become much more optimistic about its future. But has the share price recovery gone too far?

Read more »